Paper36848639
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM and 14 others. Blood Adv, 2023. Cited by 62 papers, by iCite.
Cite this record
ConductScience Library. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Papers, record 36848639. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36848639
- Disease
- paroxysmal nocturnal hemoglobinuria33 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hemoglobinuria, Paroxysmal | Major topic |
| Adult | |
| Humans | |
| Complement Inactivating Agents | |
| Hemolysis | |
| Antibodies, Monoclonal, Humanized | |
| Hemoglobins | |
| L-Lactate Dehydrogenase |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04085601 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | Derived from the trial | Yes |
Source ClinicalTrials.gov
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37180495 | A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? | Ther Adv Rare Dis | 2020 | https://conductscience.org/library/papers/37180495 | PubMed |
| 2 | 31258525 | Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. | Front Immunol | 2019 | https://conductscience.org/library/papers/31258525 | PubMed |
| 3 | 33356783 | Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. | J Manag Care Spec Pharm | 2020 | https://conductscience.org/library/papers/33356783 | PubMed |
| 4 | 37804344 | Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. | Ann Hematol | 2024 | https://conductscience.org/library/papers/37804344 | PubMed |
| 5 | 30510080 | Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. | Blood | 2019 | https://conductscience.org/library/papers/30510080 | PubMed |
| 6 | 24456505 | European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies. | Acta Oncol | 2014 | https://conductscience.org/library/papers/24456505 | PubMed |
| 7 | 24488565 | Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. | Haematologica | 2014 | https://conductscience.org/library/papers/24488565 | PubMed |
| 8 | 16990386 | The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16990386 | PubMed |
| 9 | 2478585 | Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. | J Clin Invest | 1989 | https://conductscience.org/library/papers/2478585 | PubMed |
| 10 | 35869170 | Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. | Ann Hematol | 2022 | https://conductscience.org/library/papers/35869170 | PubMed |
| 11 | 18055865 | Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. | Blood | 2008 | https://conductscience.org/library/papers/18055865 | PubMed |
| 12 | 8306954 | Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. | EMBO J | 1994 | https://conductscience.org/library/papers/8306954 | PubMed |
| 13 | 33178408 | One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. | Ther Adv Hematol | 2020 | https://conductscience.org/library/papers/33178408 | PubMed |
| 14 | 16051736 | Diagnosis and management of paroxysmal nocturnal hemoglobinuria. | Blood | 2005 | https://conductscience.org/library/papers/16051736 | PubMed |
| 15 | 11900238 | Fatigue in cancer patients compared with fatigue in the general United States population. | Cancer | 2002 | https://conductscience.org/library/papers/11900238 | PubMed |
| 16 | 22639982 | Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. | Br J Haematol | 2012 | https://conductscience.org/library/papers/22639982 | PubMed |
| 17 | 29246924 | The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. | Haematologica | 2018 | https://conductscience.org/library/papers/29246924 | PubMed |
| 18 | 34973099 | The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. | Ann Hematol | 2022 | https://conductscience.org/library/papers/34973099 | PubMed |
| 19 | 19179465 | Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. | Blood | 2009 | https://conductscience.org/library/papers/19179465 | PubMed |
| 20 | 34226670 | Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/34226670 | PubMed |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42597498 | Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42597498 | PubMed |
| 42381976 | Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42381976 | PubMed |
| 42353312 | Mitochondria: The Crossroads of Complement Activation and Kidney Injury Progression. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353312 | PubMed |
| 42322093 | Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis. | Eur J Haematol | 2026 | https://conductscience.org/library/papers/42322093 | PubMed |
| 42279078 | Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/42279078 | PubMed |
| 42185224 | Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes. | Eur J Haematol | 2026 | https://conductscience.org/library/papers/42185224 | PubMed |
| 41961736 | New Anticomplement Drugs in Nephrology: Mechanism and Indication. | Kidney Blood Press Res | 2026 | https://conductscience.org/library/papers/41961736 | PubMed |
| 41809517 | Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease. | J Blood Med | 2026 | https://conductscience.org/library/papers/41809517 | PubMed |
| 41455944 | Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations. | Cost Eff Resour Alloc | 2025 | https://conductscience.org/library/papers/41455944 | PubMed |
| 41348037 | The varieties of therapeutic experience: navigating treatment options for patients with PNH. | Hematology Am Soc Hematol Educ Program | 2025 | https://conductscience.org/library/papers/41348037 | PubMed |
| 41268092 | Paroxysmal Nocturnal Hemoglobinuria in Pregnancy Treated With Pegcetacoplan: Case Report and Pharmacokinetic Analysis. | EJHaem | 2025 | https://conductscience.org/library/papers/41268092 | PubMed |
| 41255851 | Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders. | J Blood Med | 2025 | https://conductscience.org/library/papers/41255851 | PubMed |
| 41002734 | Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies. | Diseases | 2025 | https://conductscience.org/library/papers/41002734 | PubMed |
| 40986193 | Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition. | Drugs | 2025 | https://conductscience.org/library/papers/40986193 | PubMed |
| 40777953 | The Onerous task of managing paroxysmal nocturnal hemoglobinuria in a Low resource setting: a case report. A hematologist's experience. | Afr Health Sci | 2024 | https://conductscience.org/library/papers/40777953 | PubMed |
| 40720060 | Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan. | Adv Ther | 2025 | https://conductscience.org/library/papers/40720060 | PubMed |
| 40565360 | Complement System Inhibitors in Nephrology: An Update-Narrative Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565360 | PubMed |
| 40354320 | Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy. | Blood Adv | 2025 | https://conductscience.org/library/papers/40354320 | PubMed |
| 40276419 | Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report. | Cureus | 2025 | https://conductscience.org/library/papers/40276419 | PubMed |
| 40123793 | EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial. | EJHaem | 2025 | https://conductscience.org/library/papers/40123793 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| CD55 | 1604 | PubTator's text mining | https://conductscience.org/library/genes/1604 | NCBI Gene |
| CD59 | 966 | PubTator's text mining | https://conductscience.org/library/genes/966 | NCBI Gene |
| PIGA | 5277 | PubTator's text mining | https://conductscience.org/library/genes/5277 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PEGCETACOPLAN | CHEMBL4298211 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4298211 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36848639
GET https://conductscience.org/api/papers/v1/36848639/references?page=2